Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 1999

View Archived Issues

Immtech's treatment for parasitic infections to enter phase I clinical trials

Hybridon presents HYB-165, the first orally active antitumor oligonucleotide

Chiron licenses HCV patent rights to Abbott

Cell Pathways and RPR to study Aptosyn in combination with Taxotere

Gliatech commences product development program for schizophrenia and dementia

ImmunoGen exercises put option

Licensing opportunity from NIH: globotriaosylceramide as a promoter of HIV-1 entry into cells

Northwest Biotherapeutics and Battelle form prostate cancer collaboration

NPS Pharmaceuticals and Allelix to merge

Atrix reports postmarketing study results for Atridox periodontitis therapy

York Medical to commence phase I/II trial of head and neck cancer therapy

Long-term efficacy and tolerability reported for MTX-HSA in preliminary clinical testing

Molecumetics and P&U enter collaboration for caspase research

XTL Biopharmaceuticals' human MAb enters phase I HBV trials

NeoTherapeutics initiates second phase IIb clinical trial of Neotrofin

Banyu identifies potent, selective muscarinic M3 antagonist series

Hydroxamic acid-based inhibitors of TNF-alpha production under study at Yoshitomi

Antiallergic agents described by Senju in recently issued patent

Phospholipase inhibitors synthesized and tested at Genetics Institute

New antitumor compounds from Schering-Plough act by inhibiting protein farnesyltransferase

Texas A&M describes important new class of agents for breast cancer

Novel class of quinoline-indoles: discovery, activity and pharmacokinetics discussed at ICAAC

DHFR inhibitors designed by Roche for activity against resistant Gram-positive bacteria

Levosimendan improves symptoms and prolongs survival in patients with various types of HF

News from ICAAC: characterization of water-soluble prodrug of the azole antifungal Sch-56592

Samjin's SJ-3366: a promising anti-HIV compound with a dual mechanism of action

Oral ETA antagonist ABT-627 shows signs of efficacy, safety in CHF

Detailed activity profile, predicted human pharmacokinetics of E-1010 presented at ICAAC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...